• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    1/10/24 12:31:03 PM ET
    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Sana Biotechnology (NASDAQ:SANA) shares increased by 45.2% to $7.49 during Wednesday's regular session. The company's market cap stands at $1.4 billion.
    • Amarin Corp (NASDAQ:AMRN) stock increased by 27.71% to $1.24. The company's market cap stands at $506.2 million.
    • Vicarious Surgical (NYSE:RBOT) stock moved upwards by 22.71% to $0.61. The market value of their outstanding shares is at $107.3 million.
    • Armata Pharmaceuticals (AMEX:ARMP) stock increased by 21.74% to $3.9. The company's market cap stands at $140.8 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 21.29% to $2.62. The market value of their outstanding shares is at $9.4 million.
    • Exicure (NASDAQ:XCUR) stock rose 18.4% to $0.73. The market value of their outstanding shares is at $6.3 million.

    Losers

    • DocGo (NASDAQ:DCGO) shares decreased by 35.2% to $3.1 during Wednesday's regular session. The company's market cap stands at $322.5 million.
    • Ainos (NASDAQ:AIMD) shares declined by 23.92% to $1.99. The market value of their outstanding shares is at $9.2 million.
    • Aclaris Therapeutics (NASDAQ:ACRS) stock decreased by 23.44% to $0.98. The company's market cap stands at $69.4 million.
    • TG Therapeutics (NASDAQ:TGTX) shares fell 18.12% to $17.2. The company's market cap stands at $2.6 billion.
    • RenovoRx (NASDAQ:RNXT) stock declined by 15.22% to $1.17. The company's market cap stands at $12.5 million.
    • GeneDx Hldgs (NASDAQ:WGS) shares declined by 14.68% to $3.82. The market value of their outstanding shares is at $98.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $AIMD
    $AMRN
    $ARMP

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    TG Therapeutics Inc.
    $TGTX
    10/6/2025$60.00Buy
    H.C. Wainwright
    Sana Biotechnology Inc.
    $SANA
    9/24/2025$5.00Outperform
    Wedbush
    TG Therapeutics Inc.
    $TGTX
    7/10/2025$37.00Neutral
    Goldman
    Aclaris Therapeutics Inc.
    $ACRS
    7/10/2025$6.00Overweight
    Piper Sandler
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    More analyst ratings

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bienstock Lee

    4 - DocGo Inc. (0001822359) (Issuer)

    3/31/26 7:57:38 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Feeley Kevin

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/30/26 5:38:19 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    H.C. Wainwright resumed coverage on TG Therapeutics with a new price target

    H.C. Wainwright resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $60.00

    10/6/25 8:31:23 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

    MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company's prestigious list of the World's Most Innovative Companies of 2026 as number 10 in the medical device category. This annual recognition highlights organizations that are shaping industry and culture through their innovations. "We're honored to be named one of the 2026 World's Most Innovative Medical Device Companies by Fast Company," said Shaun Bagai, Chief Executive

    4/1/26 2:20:16 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

    WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

    3/30/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    SEC Filings

    View All

    Armata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

    4/2/26 4:16:34 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    4/2/26 4:15:02 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by RenovoRx Inc.

    S-8 - RenovoRx, Inc. (0001574094) (Filer)

    3/31/26 4:19:55 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

    SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer. Mr. Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. Mr. Piper was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. "I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr, President and Chief Executive Officer of Sana. "He brings deep exper

    2/17/26 9:00:00 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

    MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management team is expected to discuss the continued progress in RenovoCath adoption among U.S. cancer centers,

    3/20/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AIMD
    $AMRN
    $ARMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by DocGo Inc.

    SC 13D/A - DocGo Inc. (0001822359) (Subject)

    11/29/24 4:14:57 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care